Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06423911 · ClinicalTrials.gov registry record · Phase 3
Study of Olverembatinib (HQP1351) in Patients With CP-CML
A Phase 3 study of Chronic Myeloid Leukemia and CML, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
- 1
- Study location
NCT06423911: Recruiting Phase 3 study of Chronic Myeloid Leukemia and CML, sponsored by Ascentage Pharma Group.
NCT06423911 is a Phase 3 study of Chronic Myeloid Leukemia and CML that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 285 participants, above the 202-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (41% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06423911, a Phase 3 study of Chronic Myeloid Leukemia and CML, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
- 1
- Study location
Study Summary
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Primary Outcome
To compare the major molecular response (MMR) rate at 24 weeks of olverembatinib versus bosutinib
Conditions Studied
Interventions
- DRUG olverembatinib
- DRUG Bosutinib
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2026-02 |
| Phase | Phase 3 |
What NCT06423911 shows while recruiting
NCT06423911 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, above the 202-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (41% higher).
The record links to 3 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which olverembatinib is the first listed.
NCT06423911 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06423911 about?
NCT06423911 is a clinical study titled "Study of Olverembatinib (HQP1351) in Patients With CP-CML". A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
What is the current status of trial NCT06423911?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2024-02-05. Estimated completion is 2026-02.
What conditions does trial NCT06423911 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, CML, CML, Chronic Phase.
What interventions are being tested in trial NCT06423911?
The interventions under investigation include: olverembatinib (DRUG), Bosutinib (DRUG).
Who is sponsoring clinical trial NCT06423911?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06423911 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06423911's enrollment target sits among peer trials
285 5th of 35 higher than 31 of 35 other Chronic Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI